PaTHway Phase 3 Trial Analysis
PaTHway Trial Patient Disposition
Randomized
N = 84
Placebo
N = 21
ITT POPULATION
Placebo Dosed
N = 21
TransCon PTH Not Treated
N = 2
(1 withdrew consent; 1 recurrence of
thyroid cancer)
TransCon PTH Discontinued Trial
N = 1
(death unrelated to study drug)
TransCon PTH
N = 63
TransCon PTH Dosed
N = 61
•
.
TransCon PTH
Completed Week 26
N = 60
Placebo
Completed Week 26
N = 19
PaTHway
TRIAL
Placebo Discontinued Trial
N = 2
(1 withdrew consent; 1 for adverse event
of breast cancer)
Intention To Treat (ITT): All randomized patients who received at least 1 dose of randomized treatment
Safety Analysis Set (SAS): All randomized patients who received at least 1 dose of randomized treatment
7 Data on file, Ascendis Pharma 2022.
TransCon PTH is an investigational product candidate.
For investor communication only.
Not for use in product promotion. Not for further distribution.
ascendis
pharmaView entire presentation